NRx Pharmaceuticals, Inc. (NRXP) has reported a significant safety advantage of their drug, NRX-101, compared to the standard treatment in a clinical trial which was conducted on patients with suicidal bipolar depression. The company asserts that this notable reduction in akathisia, combined with the comparable antidepressant efficiency, present strong grounds for the Accelerated FDA Approval of NRX-101.
NRx Pharmaceuticals has announced its plan to seek this accelerated approval for NRX-101 to be used in treating patients with bipolar depression who are at risk of akathisia. They also aim to expand the indication to include all patients with bipolar depression, and potentially, those suffering from schizophrenia.
For more health-related news, please visit rttnews.com.
